留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

TMEM家族在乳腺癌中的研究进展

裴琴 叶婷

裴琴, 叶婷. TMEM家族在乳腺癌中的研究进展[J]. 解放军医学院学报, 2023, 44(7): 806-811. doi: 10.12435/j.issn.2095-5227.2023.003
引用本文: 裴琴, 叶婷. TMEM家族在乳腺癌中的研究进展[J]. 解放军医学院学报, 2023, 44(7): 806-811. doi: 10.12435/j.issn.2095-5227.2023.003
PEI Qin, YE Ting. Research advances in novelty roles of transmembrane protein family in breast cancer[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2023, 44(7): 806-811. doi: 10.12435/j.issn.2095-5227.2023.003
Citation: PEI Qin, YE Ting. Research advances in novelty roles of transmembrane protein family in breast cancer[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2023, 44(7): 806-811. doi: 10.12435/j.issn.2095-5227.2023.003

TMEM家族在乳腺癌中的研究进展

doi: 10.12435/j.issn.2095-5227.2023.003
基金项目: 四川省科技厅-社会发展重点项目(2021YFS0226)
详细信息
    作者简介:

    裴琴,女,在读硕士。研究方向:分子肿瘤与肿瘤的分子诊断。Email: peiqin1221@163.com

    通讯作者:

    叶婷,女,博士,副教授,副主任。Email: yeting1103@163.com

  • 中图分类号: R737.9

Research advances in novelty roles of transmembrane protein family in breast cancer

More Information
  • 摘要: 跨膜蛋白(transmembrane protein,TMEM)基因家族广泛参与细胞膜结构的组成,如内质网、溶酶体和高尔基体。研究发现TMEM蛋白在乳腺癌的发生发展过程中发挥重要作用,具有促癌和(或)抑癌的双重功能。TMEM不仅参与调控乳腺癌细胞的增殖、侵袭和迁移等,同时与化疗耐药有关。因此,更好地表征TMEM家族成员在乳腺癌中的表达情况、临床意义和预后价值,探索其功能可以为肿瘤的预防和治疗提供新的思路。

     

  • 图  1  TMEM蛋白家族的结构及基本功能

    Figure  1.  Structure and basic function of TMEM protein family

    图  2  TMEM蛋白家族在乳腺癌中的作用

    Figure  2.  The roles of TMEM protein family in breast cancer

    表  1  TMEM家族蛋白分类及功能

    Table  1.   Classification and function of TMEMprotein family

     名称分类作用参考文献
    TMEM7N-末端肿瘤抑制因子[23]
    TMEM9N-末端促癌基因[36]
    TMEM16AN-末端促癌基因,平滑肌收缩[18, 38, 48, 52, 54]
    TMEM16FN-末端促癌基因[39, 40]
    TMEM17N-末端促癌基因[41, 53]
    TMEM25C-末端肿瘤抑制因子[22, 49]
    TMEM26N-末端肿瘤抑制因子[29]
    TMEM41BN-末端自噬和脂质动员[17]
    TMEM45AC-末端角质化,预后生物标志物[16, 28, 30, 60]
    TMEM48N-末端角质化[24]
    TMEM81N-末端参与预后[56]
    TMEM88N-末端促癌基因[42, 43]
    TMEM97N-末端肿瘤抑制因子[20, 31, 32, 51]
    TMEM100N-末端肿瘤抑制因子[33, 34, 61]
    TMEM116N-末端预后生物标志物[25]
    TMEM119N-末端预后生物标志物[55]
    TMEM158C-末端促癌基因[44-46, 58, 59]
    TMEM165N-末端参与高尔基糖基化[19]
    TMEM176N-末端逃避免疫系统[21]
    TMEM207N-末端预后生物标志物[25, 26]
    TMEM213N-末端预后生物标志物[25, 27]
    下载: 导出CSV
  • [1] Sung H,Ferlay J,Siegel RL,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3): 209-249. doi: 10.3322/caac.21660
    [2] DeSantis CE,Ma J,Gaudet MM,et al. Breast cancer statistics,2019[J]. CA Cancer J Clin,2019,69(6): 438-451. doi: 10.3322/caac.21583
    [3] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015版)[J]. 中国癌症杂志,2015,25(9): 692-754.
    [4] 沈松杰,孙强,黄欣,等. 中国女性乳腺癌筛查指南(2022年版)[J]. 中国研究型医院,2022,9(2): 6-13.
    [5] 张正,张雅迪,邵佳康,等. 免疫检查点抑制剂治疗三阴性乳腺癌的研究进展[J]. 解放军医学院学报,2022,43(3): 354-359. doi: 10.3969/j.issn.2095-5227.2022.03.020
    [6] Wang YB,Zhao ZY,Jiao W,et al. PRAF2 is an oncogene acting to promote the proliferation and invasion of breast cancer cells[J]. Exp Ther Med,2022,24(6): 738. doi: 10.3892/etm.2022.11674
    [7] Harbeck N,Penault-Llorca F,Cortes J,et al. Breast cancer[J]. Nat Rev Dis Primers,2019,5: 66. doi: 10.1038/s41572-019-0111-2
    [8] Zavala VA,Bracci PM,Carethers JM,et al. Cancer health disparities in racial/ethnic minorities in the United States[J]. Br J Cancer,2021,124(2): 315-332. doi: 10.1038/s41416-020-01038-6
    [9] Chen QH,Fang JL,Shen H,et al. Roles,molecular mechanisms,and signaling pathways of TMEMs in neurological diseases[J]. Am J Transl Res,2021,13(12): 13273-13297.
    [10] Weiner C,Hecht I,Kotlyar A,et al. Association of variants in TMEM45A with keratoglobus[J]. JAMA Ophthalmol,2021,139(10): 1089-1095. doi: 10.1001/jamaophthalmol.2021.3172
    [11] Yousefi M,Lee WS,Yan BG,et al. TMEM41B and VMP1 modulate cellular lipid and energy metabolism for facilitating dengue virus infection[J]. PLoS Pathog,2022,18(8): e1010763. doi: 10.1371/journal.ppat.1010763
    [12] Wu ZH,Li C,Zhang YJ,et al. Identification of a cancer stem cells signature of head and neck squamous cell carcinoma[J]. Front Genet,2022,13: 814777. doi: 10.3389/fgene.2022.814777
    [13] Schmit K,Michiels C. TMEM proteins in cancer:a review[J]. Front Pharmacol,2018,9: 1345. doi: 10.3389/fphar.2018.01345
    [14] Marx S,Dal Maso T,Chen JW,et al. Transmembrane (TMEM) protein family members:poorly characterized even if essential for the metastatic process[J]. Semin Cancer Biol,2020,60: 96-106. doi: 10.1016/j.semcancer.2019.08.018
    [15] Entova S,Billod JM,Swiecicki JM,et al. Insights into the key determinants of membrane protein topology enable the identification of new monotopic folds[J]. Elife,2018,7: e40889. doi: 10.7554/eLife.40889
    [16] Hayez A,Malaisse J,Roegiers E,et al. High TMEM45A expression is correlated to epidermal keratinization[J]. Exp Dermatol,2014,23(5): 339-344. doi: 10.1111/exd.12403
    [17] Moretti F,Bergman P,Dodgson S,et al. TMEM41B is a novel regulator of autophagy and lipid mobilization[J]. EMBO Rep,2018,19(9): e45889.
    [18] Thomas-Gatewood C,Neeb ZP,Bulley S,et al. TMEM16A channels generate Ca2+-activated Cl- currents in cerebral artery smooth muscle cells[J]. Am J Physiol Heart Circ Physiol,2011,301(5): H1819-H1827. doi: 10.1152/ajpheart.00404.2011
    [19] Foulquier F,Amyere M,Jaeken J,et al. TMEM165 deficiency causes a congenital disorder of glycosylation[J]. Am J Hum Genet,2012,91(1): 15-26. doi: 10.1016/j.ajhg.2012.05.002
    [20] Yang K,Zeng C,Wang CC,et al. Sigma-2 receptor-a potential target for cancer/alzheimer’s disease treatment via its regulation of cholesterol homeostasis[J]. Molecules,2020,25(22): 5439. doi: 10.3390/molecules25225439
    [21] Li HX,Yang WL,Zhang MY,et al. Methylation of TMEM176A,a key ERK signaling regulator,is a novel synthetic lethality marker of ATM inhibitors in human lung cancer[J]. Epigenomics,2021,13(17): 1403-1419. doi: 10.2217/epi-2021-0217
    [22] Hrašovec S,Hauptman N,Glavač D,et al. TMEM25 is a candidate biomarker methylated and down-regulated in colorectal cancer[J]. Dis Markers,2013,34(2): 93-104. doi: 10.1155/2013/427890
    [23] Zhou XL,Popescu NC,Klein G,et al. The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma[J]. Cancer Genet Cytogenet,2007,177(1): 6-15. doi: 10.1016/j.cancergencyto.2007.04.007
    [24] Qiao WL,Han YD,Jin W,et al. Overexpression and biological function of TMEM48 in non-small cell lung carcinoma[J]. Tumor Biol,2016,37(2): 2575-2586. doi: 10.1007/s13277-015-4014-x
    [25] Wrzesiński T,Szelag M,Cieślikowski WA,et al. Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors[J]. BMC Cancer,2015,15: 518. doi: 10.1186/s12885-015-1530-4
    [26] Hano K,Hatano K,Saigo C,et al. Combination of Clptm1L and TMEM207 expression as a robust prognostic marker in oral squamous cell carcinoma[J]. Front Oral Health,2021,2: 638213. doi: 10.3389/froh.2021.638213
    [27] Zou JY,Li Z,Deng H,et al. TMEM213 as a novel prognostic and predictive biomarker for patients with lung adenocarcinoma after curative resection:a study based on bioinformatics analysis[J]. J Thorac Dis,2019,11(8): 3399-3410. doi: 10.21037/jtd.2019.08.01
    [28] Flamant L,Roegiers E,Pierre M,et al. TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells[J]. BMC Cancer,2012,12: 391. doi: 10.1186/1471-2407-12-391
    [29] Nass N,Dittmer A,Hellwig V,et al. Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response[J]. Oncotarget,2016,7(25): 38408-38426. doi: 10.18632/oncotarget.9493
    [30] Lee SJ,Stewart S,Nagtegaal I,et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer[J]. Cancer Res,2012,72(17): 4574-4586. doi: 10.1158/0008-5472.CAN-12-0636
    [31] Qu TY,Zhao Y,Chen YC,et al. Down-regulated MAC30 expression inhibits breast cancer cell invasion and EMT by suppressing Wnt/β-catenin and PI3K/Akt signaling pathways[J]. Int J Clin Exp Pathol,2019,12(5): 1888-1896.
    [32] Zeng CB,Riad A,Mach RH. The biological function of Sigma-2 receptor/TMEM97 and its utility in PET imaging studies in cancer[J]. Cancers,2020,12(7): 1877. doi: 10.3390/cancers12071877
    [33] 孙恃雷. BMP9通过TMEM100抑制三阴性乳腺癌细胞的作用和机制研究[D]. 重庆: 重庆医科大学, 2020.
    [34] 黄佳欢,陈俊青,杨紫烟,等. PI3K/AKT/mTOR信号通路在三阴性乳腺癌中的作用及靶向治疗研究进展[J]. 肿瘤学杂志,2020,26(9): 784-790.
    [35] 张哲,樊俊,刘文斌,等. 跨膜蛋白196对乳腺癌迁移及侵袭能力的影响[J]. 陆军军医大学学报,2022,44(14): 1455-1465.
    [36] 彭达. TMEM9调控Wnt/β-catenin信号通路促进三阴乳腺癌细胞侵袭与迁移的机制研究[D]. 青岛: 青岛大学, 2021.
    [37] 陈奕雯. ROCK1/moesin激活TMEM16A钙激活氯通道促进乳腺癌迁移侵袭的机制研究[D]. 沈阳: 中国医科大学, 2021.
    [38] 郑雅乔. TMEM16A通过调控内质网应激的PERK信号通路促进乳腺癌细胞增殖机制的研究[D]. 沈阳: 中国医科大学, 2022.
    [39] 樊璐,王慧,肖庆桓. 跨膜蛋白16F对乳腺癌细胞增殖及迁移的影响[J]. 中国医科大学学报,2019,48(2): 124-127.
    [40] 张璐. TMEM16F通过内质网应激相关的PERK通路促进乳腺癌细胞的增殖和迁移[D]. 沈阳: 中国医科大学, 2021.
    [41] 宋奎园. TMEM17通过AKT/GSK3β信号通路促进乳腺癌的恶性进展[D]. 沈阳: 中国医科大学, 2018.
    [42] Yu XM,Zhang XP,Zhang Y,et al. Cytosolic TMEM88 promotes triple-negative breast cancer by interacting with Dvl[J]. Oncotarget,2015,6(28): 25034-25045. doi: 10.18632/oncotarget.4379
    [43] Lee HJ,Finkelstein D,Li XF,et al. Identification of transmembrane protein 88 (TMEM88) as a dishevelled-binding protein[J]. J Biol Chem,2010,285(53): 41549-41556. doi: 10.1074/jbc.M110.193383
    [44] Tong JC,Li HR,Hu Y,et al. TMEM158 regulates the canonical and non-canonical pathways of TGF-β to mediate EMT in triple-negative breast cancer[J]. J Cancer,2022,13(8): 2694-2704. doi: 10.7150/jca.65822
    [45] 童佳慈. 跨膜蛋白TMEM158通过介导EMT过程促进三阴型乳腺癌发生及发展和其分子机制研究[D]. 大连: 大连医科大学, 2022.
    [46] 朱雪峰,刘彦魁,张亚. TMEM158、CTEN在乳腺癌组织表达水平及意义[J]. 中南医学科学杂志,2020,48(6): 604-607.
    [47] Łukasiewicz S,Czeczelewski M,Forma A,et al. Breast cancer-epidemiology,risk factors,classification,prognostic markers,and current treatment strategies-an updated review[J]. Cancers (Basel),2021,13(17): 4287. doi: 10.3390/cancers13174287
    [48] 宋寒宾. 乳腺癌他莫昔芬耐药细胞中钙激活氯通道TMEM16A下调激活自噬的机制研究[D]. 沈阳: 中国医科大学, 2021.
    [49] Li Y,Wang YY,Wang HF,et al. Effects of lncRNA RP11-770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells[J]. Zhejiang Da Xue Xue Bao Yi Xue Ban,2017,46(4): 364-370.
    [50] 门欣. NPYIR和TMEM47调控乳腺癌他莫昔芬和紫杉醇多药耐药的代谢通路研究与分析[D]. 西安: 西北大学, 2021.
    [51] Zhu HF,Su ZJ,Ning J,et al. Transmembrane protein 97 exhibits oncogenic properties via enhancing LRP6-mediated Wnt signaling in breast cancer[J]. Cell Death Dis,2021,12(10): 912. doi: 10.1038/s41419-021-04211-8
    [52] 柯永莉,李黎,寇晓梅,等. 乳腺癌组织miR-381和跨膜蛋白16A表达与临床病理特征及预后的关系[J]. 中华实用诊断与治疗杂志,2022,36(7): 714-718.
    [53] Zhao Y,Song KY,Zhang Y,et al. TMEM17 promotes malignant progression of breast cancer via AKT/GSK3β signaling[J]. Cancer Manag Res,2018,10: 2419-2428. doi: 10.2147/CMAR.S168723
    [54] Crottès D,Jan LY. The multifaceted role of TMEM16A in cancer[J]. Cell Calcium,2019,82: 102050. doi: 10.1016/j.ceca.2019.06.004
    [55] Yang B,Wang FL,Zheng G. Transmembrane protein TMEM119 facilitates the stemness of breast cancer cells by activating Wnt/β-catenin pathway[J]. Bioengineered,2021,12(1): 4856-4867. doi: 10.1080/21655979.2021.1960464
    [56] 张虎,杜欣娜,庄莹,等. 乳腺癌中跨膜蛋白81基因高表达不利于患者预后[J]. 中国临床解剖学杂志,2018,36(5): 586-589.
    [57] 李健,王颜. TMEM65表达对乳腺癌患者预后的影响[J]. 山东第一医科大学(山东省医学科学院)学报,2022,43(3): 198-204.
    [58] Wang LC,Wang WH,Zeng SP,et al. Construction and validation of a 6-gene nomogram discriminating lung metastasis risk of breast cancer patients[J]. PLoS One,2020,15(12): e0244693. doi: 10.1371/journal.pone.0244693
    [59] 翁剑华,廖瑜玲,许素真. TMEM158在乳腺癌中的表达及与临床特征及预后的相关性[J]. 热带医学杂志,2019,19(1): 72-75. doi: 10.3969/j.issn.1672-3619.2019.01.018
    [60] Schmit K,Chen JW,Ayama-Canden S,et al. Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin[J]. Cell Death Dis,2019,10(12): 919. doi: 10.1038/s41419-019-2088-x
    [61] 卢晨欣. 雷公藤红素上调TMEM100蛋白抑制乳腺癌细胞MDA-MB-231转移[D]. 南充: 西华师范大学, 2017.
    [62] 张哲. 基于生物信息学分析TMEM196和NR3C2对乳腺癌患者预后的影响及功能验证[D]. 重庆: 中国人民解放军陆军军医大学, 2022.
  • 加载中
图(2) / 表(1)
计量
  • 文章访问数:  128
  • HTML全文浏览量:  69
  • PDF下载量:  9
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-11-28
  • 网络出版日期:  2023-04-14
  • 刊出日期:  2023-07-28

目录

    /

    返回文章
    返回